Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

Mosaic Therapeutics, Ltd (‘Mosaic’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology programs from Astex Pharmaceuticals (‘Astex’), a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd.

Leave a Reply